ETON PHARMACEUTICALS INC
ETONNASDAQTrading Snapshot
- Day Range
- $51.98 – $53.34
- 52-Week Range
- $14.27 – $66.37
- Volume (shares)
- 70,395.562
- Avg Volume (shares)
- —
- Shares Outstanding
- 28.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $80M
- Last Q Revenue
- $38M
- P/E Ratio
- 115.1
- P/S Ratio
- 13.8x
- EPS (TTM)
- $0.39
- Dividend Yield
- —
- Dilution (1yr)
- +3.0%
ETON PHARMACEUTICALS INC
ETON
StockOtter · stockotter.spaceAbout ETON PHARMACEUTICALS INC
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare di
Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d
Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)
Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare d